Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $58 at Mizuho Securities, Following Announcement of Troriluzole Study For Generalized Anxiety Disorder (GAD) Missing Primary Endpoint
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
